<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-9957</journal-id>
<journal-title><![CDATA[Revista colombiana de Gastroenterología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Col Gastroenterol]]></abbrev-journal-title>
<issn>0120-9957</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Gastroenterología  ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-99572017000200112</article-id>
<article-id pub-id-type="doi">10.22516/25007440.139</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Calidad de vida en pacientes con hepatitis C crónica en Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Quality of Life of Patients with Chronic Hepatitis C in Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Yepes Barreto]]></surname>
<given-names><![CDATA[Ismael de Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Carmona Meza]]></surname>
<given-names><![CDATA[Zenen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Múnera Contreras]]></surname>
<given-names><![CDATA[María Nicol]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Cartagena  ]]></institution>
<addr-line><![CDATA[Cartagena ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Pharos, Centro de Investigaciones Biomédicas de la Costa  ]]></institution>
<addr-line><![CDATA[Cartagena ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>32</volume>
<numero>2</numero>
<fpage>112</fpage>
<lpage>119</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-99572017000200112&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-99572017000200112&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-99572017000200112&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción:  los datos sobre calidad de vida en pacientes con hepatitis C son escasos en nuestro medio. A la fecha, no hay estudios que hayan determinado la carga de la enfermedad en esta población en el territorio colombiano.  Objetivos:  determinar la calidad de vida en pacientes con hepatitis C crónica e identificar sus factores determinantes utilizando la encuesta SF-36 V2.  Metodología:  estudio transversal analítico realizado desde el 1 de junio de 2015 hasta el 31 de agosto de 2015. Un encuestador entrenado aplicó la encuesta SF-36 V2 en su versión en castellano (Qualitimetric Inc.). La regresión lineal multivariante identificó los factores relacionados con la calidad de vida relacionada con la salud (CVRS). El índice de Charlson estimó el peso de las comorbilidades de la muestra.  Resultados:  41 pacientes estuvieron disponibles para el análisis. La media de edad fue de 57 años (desviación estándar [DE]: 12,6). El 50% de los sujetos presentaban cirrosis/fibrosis avanzada. El Resumen del componente físico (RCF) y el Resumen del componente mental (RCM) fueron de 48,2 y 45,6 respectivamente. El análisis de regresión lineal univariante identificó al sexo, la edad, el índice de Charlson y la presencia de cirrosis hepática como los principales determinantes de la calidad de vida. El índice de Charlson expresado como la probabilidad de supervivencia a 10 años fue el único predictor independiente del SF-6D.  Conclusión:  la edad, el sexo y la cirrosis hepática se identificaron como determinantes de la CVRS. El índice de Charlson fue el único predictor independiente de SF-6D. La implementación de programas multidisciplinarios es necesaria para el tratamiento integral de los pacientes infectados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Data on quality of life in patients with hepatitis C are scarce in our country. To date, no study has determined the burden of chronic hepatitis C in the population of Colombia.  Objectives: The objective of this study was to determine the quality of life in patients with chronic hepatitis C and to identify its determinants using the SF36V2 survey.  Methodology: This cross-sectional analytical study was conducted between June 1,2015 and August 31, 2015. A trained interviewer used the Spanish version of the SF-36 V2 survey (Quality Metric Inc.). Then multivariate linear regression identified factors related to Health Related Quality of Life (HRQL). The Charlson Comorbidity Index was used to estimate the weights of comorbidities found in the sample.  Results: Forty-one patients were available for analysis. The mean age was 57 years (SD 12.6). Fifty percent of the subjects had advanced cirrhosis and/or fibrosis. The physical component summary (PCS) and mental component summary (MCS) were 48.2 and 45.6, respectively. Univariate linear regression analysis identified sex, age, Charlson Comorbidity Index and presence of liver cirrhosis as the main determinants of quality of life. The Charlson Comorbidity Index 10-year survival probability was the only independent predictor of SFD6.  Conclusion: Age, sex and hepatic cirrhosis were identified as determinants of HRQoL. The Charlson index was the only independent predictor of SFD6. The implementation of multidisciplinary programs is necessary for comprehensive treatment of infected patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hepatitis C]]></kwd>
<kwd lng="es"><![CDATA[Colombia]]></kwd>
<kwd lng="es"><![CDATA[calidad de vida]]></kwd>
<kwd lng="es"><![CDATA[cirrosis hepática]]></kwd>
<kwd lng="es"><![CDATA[América Latina]]></kwd>
<kwd lng="es"><![CDATA[hepatitis]]></kwd>
<kwd lng="en"><![CDATA[Hepatitis C]]></kwd>
<kwd lng="en"><![CDATA[Colombia]]></kwd>
<kwd lng="en"><![CDATA[quality of life]]></kwd>
<kwd lng="en"><![CDATA[hepatic cirrhosis]]></kwd>
<kwd lng="en"><![CDATA[Latin America]]></kwd>
<kwd lng="en"><![CDATA[hepatitis.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kershenobich]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Razavi]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez-Avila]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends and projections of hepatitis C virus epidemiology in Latin America]]></article-title>
<source><![CDATA[Liver Int]]></source>
<year>2011</year>
<volume>31</volume>
<numero>^sSuppl 2</numero>
<issue>^sSuppl 2</issue>
<supplement>Suppl 2</supplement>
<page-range>18-29</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmunis FZ]]></surname>
<given-names><![CDATA[Gabriel A]]></given-names>
</name>
<name>
<surname><![CDATA[Pinheiro]]></surname>
<given-names><![CDATA[Francisco]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk for transfusion-transmitted infectious diseases in Central and South America]]></article-title>
<source><![CDATA[Emerg Infect Dis]]></source>
<year>1998</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-11</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmunis]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Zicker]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of blood supply for infectious diseases in Latin American countries, 1994-1997]]></article-title>
<source><![CDATA[Am J Trop Med Hyg]]></source>
<year>2001</year>
<volume>65</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>924-30</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Botero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Los nuevos tratamientos de hepatitis C: Perspectivas latinoamericanas]]></article-title>
<source><![CDATA[Clinical Liver Disease]]></source>
<year>2015</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yepes]]></surname>
<given-names><![CDATA[IJ LB]]></given-names>
</name>
<name>
<surname><![CDATA[Caez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores de riesgo para la infección por el virus de la hepatitis C en la Costa Caribe colombiana: un estudio de casos y controles]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2016</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>564-71</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvis]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burden of disease of hepatitis C in Colombia]]></article-title>
<source><![CDATA[Value in Health]]></source>
<year>2015</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>A250-1</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bonkovsky]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
<name>
<surname><![CDATA[Snow]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Malet]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2007</year>
<volume>46</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>420-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boscarino]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moorman]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS)]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2015</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>802-11</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El Khoury]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Vietri]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prajapati]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life in patients with hepatitis C virus infection in Brazil]]></article-title>
<source><![CDATA[Rev Panam Salud Publica]]></source>
<year>2014</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>200-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Villar]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Garbin]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of health-related quality of life and related factors in patients with chronic liver disease]]></article-title>
<source><![CDATA[Braz J Infect Dis]]></source>
<year>2015</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>590-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DiBonaventura]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Humanistic and economic impacts of hepatitis C infection in the United States]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2010</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>709-18</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Goldin]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>1998</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>209-12</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gandek]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project]]></article-title>
<source><![CDATA[Qual Life Res]]></source>
<year>2004</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>283-98</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ware J]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Turner-Bowker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gandek]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SF-12v2: how to score version 2 of the SF-12 health survey]]></article-title>
<source><![CDATA[Quality Metric Incorporated Health Assessment Lab]]></source>
<year>2002</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mhatre]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Sansgiry]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development of a conceptual model of health-related quality of life among hepatitis C patients: A systematic review of qualitative studies]]></article-title>
<source><![CDATA[Hepatol Res]]></source>
<year>2016</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-39</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sgorbini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Brien]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Living with hepatitis C and treatment: the personal experiences of patients]]></article-title>
<source><![CDATA[J Clin Nurs]]></source>
<year>2009</year>
<volume>18</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>2282-91</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheppard]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hubbert]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The patient experience of treatment for hepatitis C]]></article-title>
<source><![CDATA[Gastroenterol Nurs]]></source>
<year>2006</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>309-15</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dudley]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chaplin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Clifford]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of life after liver transplantation for hepatitis C infection]]></article-title>
<source><![CDATA[Qual Life Res]]></source>
<year>2007</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1299-308</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blacklaws]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Veysey]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interferon treatment for chronic hepatitis C: a family impact study.]]></article-title>
<source><![CDATA[Gastroenterol Nurs]]></source>
<year>2009</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>377-83</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kinder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The lived experience of treatment for hepatitis C]]></article-title>
<source><![CDATA[Gastroenterol Nurs]]></source>
<year>2009</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>401-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blasiole]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Shinkunas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Labrecque]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mental and physical symptoms associated with lower social support for patients with hepatitis C]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2006</year>
<volume>12</volume>
<numero>29</numero>
<issue>29</issue>
<page-range>4665-72</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bourliere]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bronowicki]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[de Ledinghen]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2015</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>397-404</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Younossi]]></surname>
<given-names><![CDATA[ZM]]></given-names>
</name>
<name>
<surname><![CDATA[Stepanova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Nader]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2014</year>
<volume>59</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2161-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
